Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi

Elli Mylona, Phat Voong Vinh, Sonia Qureshi, Abhilasha Karkey, Sabina Dongol, Tuyen Ha Thanh, Judd Walson, Lluis Ballell, Elena Fernandez Alvaro, Farah Qamar, Stephen Baker

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Background: Antimicrobial therapy is essential for the treatment of enteric fever, the infection caused by Salmonella serovars Typhi and Paratyphi A. However, an increase in resistance to key antimicrobials and the emergence of MDR and XDR in Salmonella Typhi poses a major threat for efficacious outpatient treatments. Objectives: We recently identified tebipenem, an oral carbapenem licensed for use for respiratory tract infections in Japan, as a potential alternative treatment for MDR/XDR Shigella spp. Here, we aimed to test the in vitro antibacterial efficacy of this drug against MDR and XDR typhoidal Salmonella. Methods: We determined the in vitro activity of tebipenem in time-kill assays against a collection of non-XDR and XDR Salmonella Typhi and Salmonella Paratyphi A (non-XDR) isolated in Nepal and Bangladesh. We also tested the efficacy of tebipenem in combination with other antimicrobials. Results: We found that both XDR and non-XDR Salmonella Typhi and Salmonella Paratyphi A are susceptible to tebipenem, exhibiting low MICs, and were killed within 8-24 h at 2-4×MIC. Additionally, tebipenem demonstrated synergy with two other antimicrobials and could efficiently induce bacterial killing. Conclusions: Salmonella Paratyphi A and XDR Salmonella Typhi display in vitro susceptibility to the oral carbapenem tebipenem, while synergistic activity with other antimicrobials may limit the emergence of resistance. The broad-spectrum activity of this drug against MDR/XDR organisms renders tebipenem a good candidate for clinical trials.

Original languageEnglish
Pages (from-to)3197-3200
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Issue number12
Publication statusPublished - 1 Dec 2021


Dive into the research topics of 'Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi'. Together they form a unique fingerprint.

Cite this